Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (SHA:600332)
China flag China · Delayed Price · Currency is CNY
19.68
+0.09 (0.46%)
Nov 17, 2026, 3:00 PM CST

SHA:600332 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
77,88377,41374,77975,27570,55068,758
Other Revenue
243.57243.57214.3240.53237.96256.1
78,12677,65674,99375,51570,78869,014
Revenue Growth
0.76%3.55%-0.69%6.68%2.57%11.90%
Cost of Revenue
66,32165,13462,51861,37357,54855,825
Gross Profit
11,80512,52212,47514,14313,24013,189
Selling, General & Admin
8,2028,3158,0038,4848,0627,955
Research & Development
803.65661.63763.77782.14819.45874.72
Other Operating Expenses
375.47241.03-46.386.38-182.76294.43
Operating Expenses
9,4809,3198,7799,3468,7539,219
Operating Income
2,3253,2033,6964,7964,4873,970
Interest Expense
-414.5-401.51-418.15-446.19-434.41-417.83
Interest & Investment Income
533.32610.46698.33751.181,048757.45
Currency Exchange Gain (Loss)
3.873.87-3.153.32-11.128.67
Other Non Operating Income (Expenses)
-106.86-41.69-27.94-45.01-41.12-94.44
EBT Excluding Unusual Items
2,3413,3743,9455,0605,0484,224
Gain (Loss) on Sale of Investments
-23.51-18.7-361.0138.64-3.59196.88
Gain (Loss) on Sale of Assets
111.8107.7411.1212.030.690.69
Asset Writedown
-8.14-3.92-2.930.42-7.06-3.08
Legal Settlements
------24.82
Other Unusual Items
267.69231.0615.71-0.364.76329.44
Pretax Income
2,6893,6903,6085,1105,0434,723
Income Tax Expense
461.14629.22606.85851.17789.87754.09
Earnings From Continuing Operations
2,2283,0613,0014,2594,2533,969
Minority Interest in Earnings
-63.38-77.6-165.24-203.65-286.85-249.11
Net Income
2,1652,9832,8354,0563,9673,720
Net Income to Common
2,1652,9832,8354,0563,9673,720
Net Income Growth
-27.52%5.21%-30.09%2.25%6.63%27.60%
Shares Outstanding (Basic)
1,6251,6261,6261,6261,6261,626
Shares Outstanding (Diluted)
1,6251,6261,6261,6261,6261,626
Shares Change
-0.03%-0.01%0.02%-0.02%--
EPS (Basic)
1.331.831.742.502.442.29
EPS (Diluted)
1.331.831.742.502.442.29
EPS Growth
-27.50%5.22%-30.10%2.27%6.63%27.61%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
872.45-1,4722,3142,4755,6154,419
Free Cash Flow Per Share
0.54-0.911.421.523.452.72
Dividend Per Share
0.7500.8500.8000.7490.7320.687
Dividend Growth
-6.25%6.25%6.81%2.32%6.55%27.69%
Gross Margin
15.11%16.13%16.63%18.73%18.70%19.11%
Operating Margin
2.98%4.12%4.93%6.35%6.34%5.75%
Profit Margin
2.77%3.84%3.78%5.37%5.60%5.39%
Free Cash Flow Margin
1.12%-1.90%3.09%3.28%7.93%6.40%
EBITDA
2,9673,8414,3305,4625,0024,390
EBITDA Margin
3.80%4.95%5.77%7.23%7.07%6.36%
D&A For EBITDA
641.68638.7634.73665.32514.44419.91
EBIT
2,3253,2033,6964,7964,4873,970
EBIT Margin
2.98%4.12%4.93%6.35%6.34%5.75%
Effective Tax Rate
17.15%17.05%16.82%16.66%15.66%15.97%
Revenue as Reported
78,12677,65674,993---
Advertising Expenses
-1,017930.481,082960.691,054